• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Marchionni L, Wilson RF, Marinopoulos SS, et al. Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Jan. (Evidence Reports/Technology Assessments, No. 160.)

Cover of Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes

Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes.

Show details

Appendix H: Excluded Articles


  1. Blanchard A, Shiu R, Booth S. et al. Gene expression profiling of early involuting mammary gland reveals novel genes potentially relevant to human breast cancer. Front Biosci. 2007;12:2221–32. [PubMed: 17127459]
  2. Charafe-Jauffret E, Ginestier C, Monville F. et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25(15):2273–84. [PubMed: 16288205]
  3. Dolled-Filhart M, Ryden L, Cregger M. et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 2006;12(21):6459–68. [PubMed: 17085660]
  4. Drubin D, Smith JS, Liu W. et al. Comparison of cryopreservation and standard needle biopsy for gene expression profiling of human breast cancer specimens. Breast Cancer Res Treat. 2005;90(1):93–6. [PubMed: 15770532]
  5. Eden P, Ritz C, Rose C. et al. “Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004;40(12):1837–41. [PubMed: 15288284]
  6. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Nat Acad Sci U S A. 2006;103(15):5923–8. [PMC free article: PMC1458674] [PubMed: 16585533]
  7. Espinosa E, Vara JA, Redondo A. et al. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol. 2005;23(29):7278–85. [PubMed: 16129846]
  8. Fielden MR, Chen I, Chittim B. et al. Examination of the estrogenicity of 2,4,6,2′,6′-pentachlorobiphenyl (PCB 104), its hydroxylated metabolite 2,4,6,2′,6′-pentachloro-4-biphenylol (HO-PCB 104), and a further chlorinated derivative, 2,4,6,2′,4′,6′-hexachlorobiphenyl (PCB 155). Environ Health Perspect. 1997;105(11):1238–48. [PMC free article: PMC1470342] [PubMed: 9370515]
  9. Girault I, Lerebours F, Amarir S. et al. Expression analysis of estrogen receptor (alpha) coregulators in breast carcinoma: Evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res. 2003;9(4):1259–1266. [PubMed: 12684393]
  10. Gradishar WJ. Hormone therapy in postmenopausal women with breast cancer. Adv Stud Med. 2005;5(9 B):S817–S822.
  11. Jansen MP, Foekens JA, van Staveren IL. et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005;23(4):732–40. [PubMed: 15681518]
  12. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert Rev Mol Diag. 2006;6(6):803–9. [PubMed: 17140367]
  13. Kominsky SL. Claudins: Emerging targets for cancer therapy. Expert Rev Mol Med. 2006;8(18):1–11. [PubMed: 16887048]
  14. Kroll T, Odyvanova L, Clement JH. et al. Molecular characterization of breast cancer cell lines by expression profiling. J Cancer Res Clin Oncol. 2002;128(3):125–134. [PubMed: 11935298]
  15. Lipka C, Mankertz J, Fromm M. et al. Impairment of the antiproliferative effect of glucocorticosteroids by 11(beta)-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast-cancer cells. Horm Metabol Res. 2004;36(7):437–444. [PubMed: 15305225]
  16. Master SR, Chodosh LA. Evolving views of involution. Breast Cancer Res. 2004;6(2):89–92. [PMC free article: PMC400663] [PubMed: 14979913]
  17. Mauriac L, Debled M, MacGrogan G. When will more useful predictive factors be ready for use? Breast. 2005;14(6):617–623. [PubMed: 16169224]
  18. Molist R, Remvikos Y, Dutrillaux B. et al. Characterization of a new cytogenetic subtype of ductal breast carcinomas. Oncogene. 2004;23(35):5986–5993. [PubMed: 15208688]
  19. Naderi A, Teschendorff AE, Barbosa-Morais NL. et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. Mar 1;26(10):1507–16. [PubMed: 16936776]
  20. Nuyten DS, Kreike B, Hart AA. et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8(5):R62. [PMC free article: PMC1779489] [PubMed: 17069664]
  21. Oehr P. Proteomics as a tool for detection of nuclear matrix proteins and new biomarkers for screening of early tumors stage. Anticancer Res. 2003;23(2 A):805–812. [PubMed: 12820304]
  22. Paik S, Kim CY, Song YK. et al. Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Onco. 2005;2(5):246–54. [PubMed: 16264960]
  23. Pusztai L. Oncogenomics 2005 - Dissecting cancer through Genome Res.: 2–6 February 2005, San Diego, CA, USA. IDrugs. 2005;8(3):215–218. [PubMed: 15772892]
  24. Ray ME, Yang ZQ, Albertson D. et al. Genomic and Expression Analysis of the 8p11–12 Amplicon in human breast cancer cell lines. Cancer Res. 2004;64(1):40–47. [PubMed: 14729606]
  25. Rha SY, Jeung HC, Yang WI. et al. Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. Oncol Rep. 2006;15(4):749–755. [PubMed: 16525654]
  26. Rodningen OK, Overgaard J, Alsner J. et al. Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. Radiother Oncol. 2005;77(3):231–40. [PubMed: 16297999]
  27. Rody A, Karn T, Gatje R. et al. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralblatt fur Gynakologi. 2006;128(2):76–81. [PubMed: 16673249]
  28. Ross DT, Perou CM. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers. 2001;17(2):99–109. [PMC free article: PMC3850857] [PubMed: 11673656]
  29. Rugo HS. Oncotype DX predicts tamoxifen benefits in ER+ breast cancer. Comment. Oncol Rep. 2005;-(FALL):18–19.
  30. Schneider J, Buness A, Huber W. et al. Systematic analysis of T7 RNA polymerase based in vitro linear RNA amplification for use in microarray experiments. BMC Genomics. 2004;5(1):29. [PMC free article: PMC419340] [PubMed: 15119961]
  31. Sengupta K, Banerjee S, Saxena NK. et al. Differential expression of VEGF-A mRNA by 17(beta)-estradiol in breast tumor cells lacking classical ER-(alpha) may be mediated through a variant form of ER-(alpha). Mol Cell Biochem. 2004;262(12):215–224. [PubMed: 15532726]
  32. Severgnini M, Bicciato S, Mangano E. et al. Strategies for comparing gene expression profiles from different microarray platforms: application to a case-control experiment. Anal Biochem. 2006;353(1):43–56. [PubMed: 16624241]
  33. Sgroi DC, Haber DA, Ryan PD. et al. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;6(5):445. [PubMed: 15542428]
  34. Sun Y, Goodison S, Li J. et al. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics. 2007;23(1):30–7. [PMC free article: PMC3431620] [PubMed: 17130137]
  35. Timar J, Ladanyi A, Petak I. et al. Molecular pathology of tumor metastasis III. Target array and combinatorial therapies. Pathology Oncology Research. 2003;9(1):49–72. [PubMed: 12704448]
  36. Verlinden I, Gungor N, Wouters K. et al. Parity-induced changes in global gene expression in the human mammary gland. Eur J Cancer Prev. 2005;14(2):129–37. [PubMed: 15785316]
  37. Weigelt B, Hu Z, He X. et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65(20):9155–8. [PubMed: 16230372]
  38. Weil MR, Widlak P, Minna JD. et al. Global survey of chromatin accessibility using DNA microarrays. Genome Res. 2004;14(7):1374–1381. [PMC free article: PMC442154] [PubMed: 15231753]
  39. Weisz A, Basile W, Scafoglio C. et al. Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol. 2004;200(3):440–450. [PubMed: 15254972]
  40. Welsh J, Wietzke JA, Zinser GM. et al. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr. 2003;133(7 SUPPL.):2425S–2433S. [PubMed: 12840219]
  41. West RB, Nuyten DS, Subramanian S. et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005;3(6):e187. [PMC free article: PMC1088973] [PubMed: 15869330]
  42. Yared MA, Middleton LP, Bernstam FM. et al. Expression of c-kit proto-oncogene product in breast tissue. Breast J. 2004;10(4):323–327. [PubMed: 15239791]
  43. Zhang JY, Casiano CA, Peng XX. et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomark Prev. 2003;12(2):136–143. [PubMed: 12582023]
PubReader format: click here to try


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...